In the final part of this slideshow series, take a look back at the novel drugs and therapeutics approved by the FDA in 2023,1 including treatments for ulcerative colitis, neutropenia, desmoid tumors, and more.
FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
April 29th 2024The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.